BamSEC and AlphaSense Join Forces
Learn More

Biocancell Therapeutics Inc.

Material Contracts Filter

EX-10.1
from 8-K 14 pages Biocancell Therapeutics Israel, Ltd. Employment Agreement With Monique Ben-Am
12/34/56
EX-10.1(IV)
from S-1/A 5 pages Amendment
12/34/56
EX-10.1
from 8-K 13 pages Biocancell Therapeutics Israel, Ltd. Employment Agreement With Jonathan Burgin
12/34/56
EX-10.30
from S-1/A 1 page November 12, 2010 via Email Biocancell Therapeutics Inc. 8 Hartom St. Pob 45389 Jerusalem, Israel 91451 Attn: Uri Danon, Chief Executive Officer Re: Termination of October 19, 2010 Letter Agreement Sincerely Yours, Chardan Capital Markets, LLC
12/34/56
EX-10.29
from S-1/A 1 page Biocancell Therapeutics Inc. 8 Hartom St. Pob 45389 Jerusalem, Israel 91451 November 8, 2010
12/34/56
EX-10.26
from S-1/A 2 pages - Convenience Translation From Hebrew - Agreement Singed and Entered Into in Tel Aviv This __ Day of , 2010 by and Between Biocancell Therapeutics Inc. (The “Company”) and Clal Finance Batucha Investment Management Ltd
12/34/56
EX-10.28
from S-1/A 9 pages (A) Familiarize Itself to the Extent Appropriate and Feasible With the Business, Operations, Properties, Financial Condition and Prospects of the Company, It Being Understood That Advisor Shall Be Entitled, in the Course of Such Familiarization, to Rely Upon Publicly Available Information and Such Other Information as May Be Supplied by the Company, Without Independent Investigation; (B) Conduct Road Shows to Introduce the Company to Potential Investors; (C) Advise and Assist the Company in Negotiating the Terms and Conditions of the Above Defined Transaction; Biocancell Therapeutics Inc
12/34/56
EX-10.27
from S-1/A 3 pages Agreement
12/34/56
EX-10.26
from S-1/A 2 pages - Convenience Translation From Hebrew - Agreement Singed and Entered Into in Tel Aviv This __ Day of , 2010 by and Between Biocancell Therapeutics Inc. (The “Company”) and Clal Finance Batucha Investment Management Ltd
12/34/56
EX-10.15
from S-1/A 55 pages Therefore, the Parties Agreed, Acknowledged and Stated the Following
12/34/56
EX-10.1
from 8-K 2 pages Employment Agreement
12/34/56
EX-10.2
from S-1/A 44 pages Company Plasmid Dna Production Agreement
12/34/56
EX-10.2
from S-1/A 19 pages Company Plasmid Dna Production Agreement
12/34/56
EX-10.24
from S-1/A 28 pages Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between ‘Keren Mechkarim’ of Bnai-Zion Medical Center Haifa, Israel
12/34/56
EX-10.23
from S-1/A 29 pages Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between the Fund for Medical Research, Development of Infrastructure and Health Services (Hereinafter: “The Fund”) Assaf Harofeh Fund, Zerifin 70300, Israel
12/34/56
EX-10.22
from S-1/A 32 pages Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between Hadasit Medical Research Services and Development Ltd. Hadassah Ein-Kerem Hospital P.O.BOX 12000 Jerusalem, Israel
12/34/56
EX-10.21
from S-1/A 33 pages Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between the Fund of Medical Research Development of Infrastructure and Health, Hillel Yaffe Medical Center
12/34/56
EX-10.20
from S-1/A 28 pages Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between
12/34/56
EX-10.15
from S-1/A 52 pages Therefore, the Parties Agreed, Acknowledged and Stated the Following
12/34/56
EX-10.19
from S-1 26 pages Subscription and Registration Rights Agreement
12/34/56